Sight Sciences, Inc.

Sight Sciences, Inc. is an eyecare technology company dedicated to developing and commercializing transformative, interventional solutions for prevalent eye diseases. Incorporated in Delaware in 2010, the company's mission is to empower eyecare providers to elevate the standards of care by offering innovative technologies that address the underlying causes of chronic eye conditions. Its headquarters are located in Menlo Park, California.

The company's product portfolio is segmented into Interventional Glaucoma and Interventional Dry Eye. Key offerings in the Interventional Glaucoma segment include the OMNI Surgical System and the SION Surgical Instrument, which are minimally invasive technologies designed to reduce intraocular pressure in adult patients with primary open-angle glaucoma. For Interventional Dry Eye, Sight Sciences offers the TearCare System, an in-office device cleared for localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction.

Paul Badawi serves as the Founder and CEO of Sight Sciences. The company is publicly traded on the Nasdaq exchange under the ticker symbol SGHT. Recent developments include the launch of the OMNI Edge Surgical System in April 2025, an advanced technology for minimally invasive glaucoma surgery, and positive advancements in Medicare coverage for its TearCare system. Sight Sciences also secured a jury verdict and monetary damages against Alcon in a patent infringement case.